Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol. Oncol. 115, 112–120 (2009).

Low-grade serous ovarian cancer (LGSC), accounts for just 5% to 10% of all epithelial ovarian cancers, but its distinct ...

Tumor markers can help healthcare professionals diagnose pancreatic cancer. Learn more here. ... People who have ovarian cancer often have high levels of CA 125 in their blood.

1 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Michigan Medical Center, Ann Arbor, MI 2 Department of Internal Medicine Division of Gynecologic Oncology ...

CAR-T therapy targeting TM4SF1 in aggressive bladder cancer (HV) histologic variant , offering hope for treatment-resistant ...

Impact of Tumor Heterogeneity on Testing Reliability. Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, considerations include the ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

A diagnosis of 4 stage ovarian cancer can be devastating. However, advances in medical science are helping patients and offering them hope ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...